UNSPSC 51451608: Dribendazole

This classification denotes an antihelminthic agent with the molecular formula C15H19N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5491IVP21O, chemically known as carbamic acid, (5-(cyclohexylthio)-1h-benzimidazol-2-yl)-,methyl ester but generally known as dribendazole, which bears US NIH Compound Identifier 170311. European Medicines Agency schedules Dribendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06399MIG.

UNSPSC 51451608 Dribendazole is a Commodity code that nominally identifies a specific anthelmintic pharmaceutical ingredient, but recent state and local opportunities tagged under this code show no direct procurement of dribendazole itself. Instead, the four most recent solicitations involve broader pharmaceutical and medical supply acquisitions: naloxone and drug deactivation systems, direct-to-manufacturer pharmacy benefit programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing. The scope mismatch between the code's nominal content and actual buying activity suggests the code sees minimal or misclassified procurement volume in state and local markets. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota MMCAP). The mismatch between code definition and actual procurement needs warrants verification before pursuing opportunities tagged under this classification.

Recent activity spans Florida, Texas, Minnesota, and Oregon, reflecting both single-jurisdiction procurement and multistate cooperative purchasing models. The most recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response due July 26, 2023); the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response due April 3, 2026); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000.00 with a Small Local Business Enterprise set-aside and 5% bid discount (response due March 13, 2026); and the Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities, responses due March 26, 2026. The code shows limited decision-relevance for firms targeting pharmaceutical manufacturing or specialty anthelmintic distribution unless pursuing opportunities through wholesale or cooperative-purchasing channels in healthcare procurement.